Lisata Therapeutics, Inc.
LSTA
$1.09
-$0.04-3.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -8.83% | 82.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.22% | 55.46% | |||
| Operating Income | 19.22% | -60.51% | |||
| Income Before Tax | 39.93% | -65.06% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 34.75% | -51.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 34.75% | -51.96% | |||
| EBIT | 19.22% | -60.51% | |||
| EBITDA | 19.25% | -61.23% | |||
| EPS Basic | 35.45% | -48.51% | |||
| Normalized Basic EPS | 40.13% | -60.01% | |||
| EPS Diluted | 35.45% | -48.51% | |||
| Normalized Diluted EPS | 40.13% | -60.01% | |||
| Average Basic Shares Outstanding | 1.11% | 2.33% | |||
| Average Diluted Shares Outstanding | 1.11% | 2.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||